There is no optimal age for treatment of hepatitis B major triple-positive, and treatment depends mainly on the degree of liver damage and the severity of the disease. Major triple yang refers to chronic hepatitis B patients and hepatitis B virus carriers who have three positive immune indicators of the hepatitis B virus in their bodies, namely hepatitis B surface antigen, hepatitis B e antigen and hepatitis B core antibody. A positive level of these three indicators often indicates that the virus is actively replicating in the body, but whether it causes serious liver cell damage depends on liver function tests and the patient’s self-perceived symptoms. It does not mean that the disease is serious, but a positive index of the above three indicators only reflects the immune status of the virus when it is present in the body. Generally, when the liver function is significantly abnormal and the virus is replicating in a moderate or large amount, then the treatment is targeted, such as antiviral therapy or interferon therapy.